13:41 , Apr 13, 2018 |  BC Week In Review  |  Company News

Otsuka gets Japanese rights to Takara's TCR, CAR therapies

Takara Bio Inc. (Tokyo:4974) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) exclusive co-development and Japanese commercialization rights to cancer candidates TBI-1301, a cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-targeted short interfering T cell receptor therapy, and TBI-1501,...
22:49 , Apr 10, 2018 |  BC Extra  |  Company News

Otsuka gets Japanese rights to Takara's TCR, CAR therapies

Takara Bio Inc. (Tokyo:4974) granted Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) co-development and exclusive Japanese commercialization rights to cancer candidates TBI-1301, a cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-targeted short interfering T cell receptor therapy, and TBI-1501,...